Erythrocytes As Drug Carriers In Medicine-..

Código: 1020705 Marca: Springer Publishing

R$ 1.825,92

até 4x de R$ 456,48 sem juros

ou R$ 1.734,62 via Pix

Qtde: Adicionar ao carrinho Disponibilidade: 45 dias úteis Estoque: 208 unidades

Parcelas
- 1x de R$ 1.825,92 sem juros
- 2x de R$ 912,96 sem juros
- 3x de R$ 608,64 sem juros
- 4x de R$ 456,48 sem juros
R$ 1.734,62
R$ 1.825,92

The sixth meeting on the use of resealed annealed red blood cells was held in Irsee, Germany by the International Society for the Use of Resealed Erythrocytes (ISURE) on July 25-28, 1996. Although earlier meetings focused on the technology toward develop- ment of methods and standardization for efficient, consistent encapsulation, most of the present studies now are directed toward the application use of these carrier blood cells. Basic studies now have been directed toward exploration of commercial applications. In- deed, clinical trials were initiated to evaluate the dose-response curves employing L- asparagenase in human patients. Also, studies have shown the use of thrombolytic agent in erythrocyte carriers with the use of human red blood cells to provide a new conceptual ap- proach in thrombolytic therapy to prevent thrombosis in individuals with higher risk fac- tors. For example, with the use of carrier red blood cells, the thrombolytic agents will have a greater potential of acting on clot formation without systemic activation and thus lower the risk of hemorrhage, which is always prevalent in the thrombolytic therapy.

ISBN	9780306455995
Autor(a)	Sprandel, Ulrich
Editora	Springer Publishing
Ano de edição	1997
Páginas	150
Acabamento	Capa Dura